Lili Zhang

Lili Zhang has extensive drug discovery experience in Alzheimer’s and neurodegenerative diseases. Prior to Dewpoint she was senior director at a startup company Aquinnah Pharmaceuticals where she led the efforts of developing treatment for ALS and Alzheimer’s using stress granule approach. Before that she worked on Alzheimer’s disease for 20 years in Schering-Plough, Merck and Novartis. She has led and supported γ-secretase inhibitor and modulator, O-GlcNAcase (OGA) inhibitor, BACE inhibitor, Aß and tau antibody projects that delivered multiple preclinical and clinical candidates. She is a biochemist by training and believes biomarker is a key component bridging preclinical drug discovery to clinical development for neurodegenerative diseases.

Lili has published over 40 peer reviewed papers. She also serves as a scientific reviewer for NIH and Alzheimer’s Association’s drug development programs. Outside work she enjoys running, alone or with friends. This picture is her virtual run with Team End Alz for 2020 Boston Marathon, on the first Patriots Day in 124 years that the city missed the Marathon.